DelveInsight’s, “IgA Nephropathy Pipeline Insight, 2025,” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in IgA Nephropathy pipeline landscape. It covers the IgA Nephropathy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the IgA Nephropathy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the IgA Nephropathy Treatment Landscape @ IgA Nephropathy Pipeline Outlook

Key Takeaways from the IgA Nephropathy Pipeline Report

• On August 15, 2025, Novartis Pharmaceuticals announced the initiation of a clinical trial designed to assess the impact of BION-1301 compared with placebo on proteinuria in adults with IgA nephropathy (IgAN). The trial plans to enroll around 330 participants with biopsy-confirmed IgAN and an eGFR ≥ 30 mL/min/1.73m², who will be randomized to receive either 600 mg of BION-1301 every two weeks (Q2W) or a matching placebo for a period of 104 weeks. In addition, an exploratory cohort of about 20 participants (10 per arm) with biopsy-proven IgAN and an eGFR between ≥20 and
• On August 15, 2025, Alexion Pharmaceuticals, Inc. announced the launch of the I CAN study, which aims to recruit approximately 510 participants with IgAN who are at high risk of disease progression. Eligible participants must have been on stable standard-of-care IgAN therapies for at least three months prior to screening. Of these, around 450 participants will be randomized in a 1:1 ratio to receive either ravulizumab (weight-based IV infusion) or placebo, in addition to their background treatment.
• On August 12, 2025, Biogen announced the initiation of a study to evaluate the impact of felzartamab on proteinuria. The trial aims to gain deeper insights into the potential of felzartamab in patients with immunoglobulin A nephropathy (IgAN). Specifically, the study will target individuals experiencing proteinuria, a condition resulting from kidney damage.
• DelveInsight’s IgA Nephropathy pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for IgA Nephropathy treatment.
• The leading IgA Nephropathy Companies such as Chinook Therapeutics, Guangdong Hengrui Pharmaceutical Co., Ltd., Takeda, Visterra, Novartis Pharmaceuticals, Wuhan Createrna Science and Technology, Jiangsu HengRui Medicine Co., Ltd., Selecta Biosciences, and Shanghai Alebund Pharmaceuticals and others.
• Promising IgA Nephropathy Pipeline Therapies such as LNP023, Blisibimod, Intravenous Rituximab, BION-1301, Atrasentan, TARPEYO®, HRS-5965 and others.

Stay informed about the cutting-edge advancements in IgA Nephropathy treatments. Download for updates and be a part of the revolution in Genito Urinary System and Steroid Hormones Care @ IgA Nephropathy Clinical Trials Assessment

IgA Nephropathy Emerging Drugs Profile

• Atrasentan: Chinook Therapeutics

Atrasentan is a potent and selective inhibitor of the endothelin A receptor (ETA) that has the potential to provide benefit in multiple chronic kidney diseases by reducing proteinuria and having direct anti-inflammatory and anti-fibrotic effects to preserve kidney function. Chinook selected IgAN as the lead indication for atrasentan due to the role of ETA activation in driving proteinuria, mesangial cell activation, kidney inflammation and fibrosis, the hallmarks of IgAN disease progression. Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of IgA Nephropathy.

• SHR-2010: Guangdong Hengrui Pharmaceutical Co., Ltd.

SHR-2010 is a drug being studied for the treatment of Primary IgA Nephropathy. It is an injection developed by Guangdong Hengrui Pharmaceutical Co., Ltd., currently in Phase II of research. The drug is aimed at inhibiting MASP2protein. Clinical trials are ongoing to evaluate the efficacy, safety, and pharmacokinetics of SHR-2010 in patients with Primary IgA Nephropathy.

• TAK-079: Takeda

TAK-079, also known as mezagitamab, targets CD38-expressing cells, including plasmablasts, plasma cells, and natural killer cells, leading to their depletion. The rationale for using TAK-079 in IgA nephropathy is that by reducing plasma cells responsible for producing the abnormal IgA1 protein, it may help prevent the formation of pathogenic immune complexes and subsequent kidney injury. In a Phase 1b clinical trial, TAK-079 is being evaluated for safety, tolerability, pharmacokinetics, and efficacy in patients with primary IgA nephropathy who are receiving stable background therapy.

The IgA Nephropathy Pipeline Report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of IgA Nephropathy with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for IgA Nephropathy Treatment.
• IgA Nephropathy Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• IgA Nephropathy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the IgA Nephropathy market.

Learn more about IgA Nephropathy Drugs opportunities in our groundbreaking IgA Nephropathy research and development projects @ IgA Nephropathy Unmet Needs

IgA Nephropathy Companies

Chinook Therapeutics, Guangdong Hengrui Pharmaceutical Co., Ltd., Takeda, Visterra, Novartis Pharmaceuticals, Wuhan Createrna Science and Technology, Jiangsu HengRui Medicine Co., Ltd., Selecta Biosciences, and Shanghai Alebund Pharmaceuticals and others.

IgA Nephropathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous

• Subcutaneous

• Oral

• Intramuscular

IgA Nephropathy Products have been categorized under various Molecule types such as

• Monoclonal antibody

• Small molecule

• Peptide

Stay informed about how we’re transforming the future of Genito Urinary System and Steroid Hormones @ IgA Nephropathy Market Drivers and Barriers, and Future Perspectives

Scope of the IgA Nephropathy Pipeline Report

• Coverage- Global
• IgA Nephropathy Companies- Chinook Therapeutics, Guangdong Hengrui Pharmaceutical Co., Ltd., Takeda, Visterra, Novartis Pharmaceuticals, Wuhan Createrna Science and Technology, Jiangsu HengRui Medicine Co., Ltd., Selecta Biosciences, and Shanghai Alebund Pharmaceuticals and others.
• IgA Nephropathy Pipeline Therapies- LNP023, Blisibimod, Intravenous Rituximab, BION-1301, Atrasentan, TARPEYO®, HRS-5965 and others.
• IgA Nephropathy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• IgA Nephropathy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of IgA Nephropathy Pipeline on our website @ IgA Nephropathy Emerging Drugs and Companies

Table of Contents

1. Introduction
2. Executive Summary
3. IgA Nephropathy: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. IgA Nephropathy- DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Atrasentan: Chinook Therapeutics
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. SHR-2010: Guangdong Hengrui Pharmaceutical Co., Ltd.
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. TAK-079: Takeda
15. Preclinical and Discovery Stage Products
16. Product Name: Company Name
17. Inactive Products
18. IgA Nephropathy Key Companies
19. IgA Nephropathy Key Products
20. IgA Nephropathy- Unmet Needs
21. IgA Nephropathy- Market Drivers and Barriers
22. IgA Nephropathy- Future Perspectives and Conclusion
23. IgA Nephropathy Analyst Views
24. IgA Nephropathy Key Companies
25. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/iga-nephropathy-igan-pipeline-insight